Probiotic Consortium Lowered Cholesterol in Mice: The Bile Salt Hydrolase Mechanism

This preclinical study in Scientific Reports tested a multi-strain probiotic consortium -- the Lab4 mix plus Lactobacillus plantarum CUL66 -- in C57BL/6J mice fed a high-fat diet for two weeks. Two weeks of supplementation significantly lowered plasma total cholesterol and suppressed diet-induced weight gain, while bile acid analysis pointed to bile salt hydrolase activity as the most likely mechanism. The work is one of the cleanest mechanistic demonstrations of how specific gut bacteria can shift cholesterol biology and sits alongside human trials of bile-salt-hydrolysing probiotic strains in the gut-cardiovascular axis literature.

Why This Study Matters

Population studies had already shown that gut microbiome composition explains a meaningful share of blood lipid variance in free-living humans. What those observational findings did not tell you was why -- what specific bacterial activity translates a stool sample into a cholesterol number on a lab panel. Without a mechanism, "probiotics lower cholesterol" was a correlation in search of an explanation.

This trial tested a specific hypothesis: that bile salt hydrolase activity from probiotic bacteria is a proximal mechanism behind the cholesterol effect. Bile salt hydrolases are bacterial enzymes that deconjugate bile acids in the small intestine, making them less easily reabsorbed. The body then has to pull circulating cholesterol back into the liver to synthesise new bile acids, which lowers plasma cholesterol. The same enzyme family is the working mechanism behind several human probiotic RCTs already in the literature.

The researchers picked a consortium -- the Lab4 mix (a defined blend of Lactobacillus acidophilus, L. salivarius, and two Bifidobacterium strains) plus L. plantarum CUL66 -- and asked whether two weeks of feeding it to high-fat-fed mice would lower cholesterol, suppress weight gain, and shift the bile acid profile in the direction the bile salt hydrolase hypothesis predicts. The value of the study isn't the effect size; it's the mechanistic chain it lets you reconstruct end-to-end.

How It Was Designed

The basics are in the study design bar above: high-fat-fed C57BL/6J mice, two-week supplementation with Lab4 plus L. plantarum CUL66, Cultech and Cardiff University collaboration. A few design choices are worth highlighting.

The trial used a layered evidence design rather than just a single in vivo experiment. The researchers first established, in cultured Caco-2 enterocytes, that the Lab4 consortium could hydrolyse bile salts, assimilate cholesterol, and modulate cholesterol transport across the gut epithelium. Only after the cell-line evidence supported the mechanism did they move to the animal model. That sequencing matters: if the in vivo effect appeared without the cell-line mechanism showing up first, you'd have a much weaker case for which biology is doing the work.

The C57BL/6J strain on a high-fat diet is a standard preclinical model for diet-induced hypercholesterolaemia and weight gain, which makes the results directly comparable to a large existing literature on cholesterol-lowering interventions in mice. Plasma was profiled for total cholesterol, VLDL/LDL, HDL, triglycerides, cytokines, and circulating bile acids; the liver was profiled for mRNA expression of cholesterol-7α-hydroxylase (CYP7A1) and small heterodimer partner (SHP), the two transcription targets that change when intestinal bile acid signalling is disrupted; and faeces were analysed for total and unconjugated bile acid content.

The combination matters. A drop in plasma cholesterol on its own could be explained by any number of mechanisms. A drop in plasma cholesterol plus increased faecal unconjugated bile acids plus altered CYP7A1/SHP expression in the liver is a coherent fingerprint of bile salt hydrolase activity specifically.

What They Found

After two weeks of high-fat diet plus the probiotic consortium, the treated mice differed from controls on the markers most directly tied to the bile salt hydrolase mechanism, and notably did not differ on several other lipid and inflammatory markers.

Outcome	Direction vs. Control	Significance	What It Measures
Plasma total cholesterol	Significantly lower	Significant	Total circulating cholesterol
Diet-induced weight gain	Significantly suppressed	Significant	Weight accrual on high-fat diet
Faecal total bile acids	Increased	Significant	Bile acid excretion via stool
Faecal unconjugated bile acids	Increased	Significant	Direct readout of BSH activity
Hepatic CYP7A1 / SHP mRNA	Modulated	Significant	Liver bile acid synthesis response
Plasma VLDL/LDL, HDL, triglycerides	No change	Not significant	Lipoprotein subfractions
Plasma cytokines and bile acids	No change	Not significant	Systemic inflammation, circulating BA

Green indicates a favorable direction or a mechanistic shift consistent with the bile salt hydrolase hypothesis. All significant differences are reported at p < 0.05.

The most informative line in the table is the combination of the third and fourth rows. Increased unconjugated bile acids in the stool is the direct biochemical signature of bacterial bile salt hydrolase activity in the gut. Pair that with the drop in plasma total cholesterol and the change in hepatic CYP7A1/SHP expression, and you have a complete mechanistic loop: bacterial enzymes deconjugate bile acids in the intestine; deconjugated bile acids are excreted rather than reabsorbed; the liver compensates by synthesising new bile acids from circulating cholesterol; plasma cholesterol falls.

Reading the Results

The findings group into mechanism, lipid biology, and what stayed quiet.

The mechanism (faecal bile acids, hepatic gene expression). This is the core of the paper. The Caco-2 cell experiments showed the consortium could hydrolyse bile salts in vitro. The in vivo data then showed that the same activity appeared in mice: faecal unconjugated bile acid output rose, and the liver's bile acid synthesis programme -- governed by CYP7A1 and the SHP transcription factor -- shifted in the direction you would expect if the intestinal bile acid pool were being depleted. Each piece is interpretable on its own; together, they pin down bile salt hydrolase activity as a working mechanism rather than a plausible one.

The lipid biology (total cholesterol down, lipoprotein fractions unchanged). The drop showed up in total cholesterol but not in the individual lipoprotein fractions measured in this study. Two weeks is a short window, and mouse lipid biology compartmentalises cholesterol differently than human biology does, so this pattern is best read as "the intervention shifted cholesterol load" rather than as a specific claim about LDL or HDL. The interesting contrast with the human population data on this axis is the inverse: population-scale microbiome variance shows up on triglycerides and HDL but not on total or LDL cholesterol. The two findings are not in conflict; they are measuring different things, in different organisms, on different timescales.

What stayed quiet (cytokines, plasma bile acids). Plasma cytokine profiles did not change, which argues against a generalised systemic inflammatory or immune mechanism for the cholesterol effect. Circulating bile acids also did not change, which is consistent with the action being local to the gut rather than systemic -- exactly what the bile salt hydrolase model predicts.

What Didn't Change

No significant differences in plasma VLDL/LDL, HDL, or triglycerides; no changes in circulating cytokines or plasma bile acids. The intervention's footprint was specifically on total cholesterol, weight, faecal bile acid chemistry, and hepatic gene expression -- not on systemic inflammation or the individual lipoprotein fractions.

The other obvious limit is that this is a mouse study. Mice are not humans; high-fat-fed C57BL/6J mice are not adults with mild hypercholesterolaemia; two weeks is not a clinically relevant duration; and the consortium tested here is a specific commercial blend rather than a generic claim about "probiotics." The value of this paper is mechanism, not effect size. It supports the case that human probiotic trials targeting bile salt hydrolase strains should expect the cholesterol pathway to be involved -- which is what the parallel L. reuteri and L. plantarum human RCTs went on to test.

Broader Context

This paper fits into a tightly connected cluster of work on bile salt hydrolase activity and cholesterol. Human RCTs of L. reuteri NCIMB 30242 (Jones et al., 2012) and a three-strain L. plantarum consortium (Fuentes et al., 2013) both reported clinically meaningful LDL reductions and both attributed the mechanism to bacterial deconjugation of bile salts. The 2015 LifeLines-DEEP analysis from Fu and colleagues then showed, at population scale, that gut microbiome composition explains about 6% of triglyceride and 4% of HDL variance independent of host genetics. This 2017 mouse trial sits in the mechanistic middle of those bookends: it shows, in a controlled animal model, that a defined probiotic mixture produces the bile acid fingerprint the human trials implicate.

The Tarabanis et al. 2023 narrative review on olive polyphenols and cardiovascular endpoints explicitly maps the gut-cardiovascular axis as a bridge cluster -- evidence that gut bacteria modulate cardiovascular risk through bile acid handling, short-chain fatty acid production, and inflammation -- and cites the same strands of probiotic and microbiome work referenced here.

What makes this 2017 trial useful in the broader literature is methodological. By layering Caco-2 cell evidence, in vivo cholesterol and weight outcomes, faecal bile acid chemistry, and hepatic gene expression in a single paper, it lets readers follow the mechanism from enzyme to plasma. Most probiotic-cholesterol papers report only one or two of those layers; this one reports all of them.

Related Research

Continue exploring olive oil and polyphenol science:

• L. reuteri NCIMB 30242 Lowered Cholesterol: A Bile Salt Hydrolase RCT
• L. plantarum CECT 7527/7528/7529 Lowered LDL: A 12-Week RCT
• Gut Microbiome Explains 6% of Triglyceride Variance in 893 Adults

Source: View the original study on PubMed

Olivea's Dosage

This study did not test an Olivea product. It is a preclinical mechanistic trial of a specific probiotic consortium in mice, run by Cultech and Cardiff University researchers and unrelated to Olivea. Olivea's current lineup -- extra virgin olive oil and the polyphenol capsule -- is built around hydroxytyrosol and the broader olive polyphenol profile rather than live probiotics. The bile salt hydrolase mechanism characterised in this paper is one of the clearest threads in the gut-cardiovascular axis evidence base; the current third-party certificate of analysis documents what is in the existing products.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.